Trials / Completed
CompletedNCT01791920
To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines
Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of "Botulax®" Compared to Botox Inj. in Patients With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 262 (actual)
- Sponsor
- Hugel · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To compare the safety and efficacy of Botulax® with Botox® in the improvement of moderate to severe glabellar lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum toxin type A(Botulax®) | Single administration, Day 0, 20 units |
| DRUG | Botulinum toxin type A(Botox®) | Single administration, Day 0, 20units |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2011-12-01
- Completion
- 2012-03-01
- First posted
- 2013-02-15
- Last updated
- 2022-04-15
Locations
6 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01791920. Inclusion in this directory is not an endorsement.